CN104603150A - 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体 - Google Patents

与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体 Download PDF

Info

Publication number
CN104603150A
CN104603150A CN201380020974.XA CN201380020974A CN104603150A CN 104603150 A CN104603150 A CN 104603150A CN 201380020974 A CN201380020974 A CN 201380020974A CN 104603150 A CN104603150 A CN 104603150A
Authority
CN
China
Prior art keywords
seq
antibody
variable region
ige
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380020974.XA
Other languages
English (en)
Chinese (zh)
Inventor
张子文
陈君柏
林健仁
陈念宜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of CN104603150A publication Critical patent/CN104603150A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
CN201380020974.XA 2012-04-20 2013-03-14 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体 Pending CN104603150A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636618P 2012-04-20 2012-04-20
US61/636,618 2012-04-20
PCT/US2013/031454 WO2013158274A1 (fr) 2012-04-20 2013-03-14 Anticorps anti-mige (ige liées à la membrane) qui se lient à la jonction entre les domaines ch4 et cεmx

Publications (1)

Publication Number Publication Date
CN104603150A true CN104603150A (zh) 2015-05-06

Family

ID=49383926

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380020974.XA Pending CN104603150A (zh) 2012-04-20 2013-03-14 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体

Country Status (4)

Country Link
US (1) US9587034B2 (fr)
EP (1) EP2838919A4 (fr)
CN (1) CN104603150A (fr)
WO (1) WO2013158274A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105542004A (zh) * 2016-01-12 2016-05-04 中国人民解放军军事医学科学院生物工程研究所 一种抗破伤风毒素的中和性单克隆抗体及其应用
TWI821209B (zh) * 2017-10-31 2023-11-11 合一生技股份有限公司 治療IgE介導的過敏性疾病

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10047166B2 (en) * 2014-06-17 2018-08-14 Academia Sinica Humanized anti-IgE antibodies that crosslink CD23 on B lymphocytes but do not sensitize mast cells
EP3606554A4 (fr) * 2017-04-05 2020-12-09 Astute Medical, Inc. Dosages pour timp2 ayant une efficacité améliorée dans des échantillons biologiques
CN116925216B (zh) * 2022-04-11 2024-09-24 东莞市朋志生物科技有限公司 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5690934A (en) 1987-12-31 1997-11-25 Tanox Biosystems, Inc. Peptides relating to the extracellular membrane-bound segment of human alpha chain
US5260416A (en) 1987-12-31 1993-11-09 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted IgE
US5274075A (en) 1987-12-31 1993-12-28 Tanox Biosystems, Inc. Newly identified human epsilon immunoglobulin peptides and related products
EP0407392B2 (fr) 1987-12-31 1998-10-28 Tanox Biosystems, Inc. Epitopes antigeniques uniques sur des lymphocytes b porteurs d'immunoglobuline e
US5514776A (en) 1987-12-31 1996-05-07 Tanox Biosystems, Inc. Peptides representing antigenic epitopes of dog IgE present on B cell but not basophil surface
US5484907A (en) 1989-06-21 1996-01-16 Tanox Biosystems, Inc. Nucleotides coding for the extracellular membrane-bound segment of IgA
US5089603A (en) 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
US5614611A (en) 1987-12-31 1997-03-25 Tanox Biosystems, Inc. Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
US5422258A (en) 1987-12-31 1995-06-06 Tanox Biosystems, Inc. Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5362643A (en) 1989-06-21 1994-11-08 Tanox Biosystems Antibodies to epitopes present on membrane-bound but not secreted IGA
US5252467A (en) 1987-12-31 1993-10-12 Tanox Biosystems, Inc. Method of making antibodies to antigenic epitopes of IGE present on B cells but not basophil cell surface or secreted, soluble IGE
US5079344A (en) 1989-06-21 1992-01-07 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted IgA
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5342924A (en) 1987-12-31 1994-08-30 Tanox Biosystems, Inc. Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
US5254671A (en) 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
US5231026A (en) 1987-12-31 1993-07-27 Tanox Biosystems, Inc. DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE
US5292867A (en) 1988-11-16 1994-03-08 Tanox Biosystems, Inc. Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5310875A (en) 1989-06-21 1994-05-10 Tanox Biosystems, Inc. Peptides corresponding to membrane-bound IgA
EP0493446B1 (fr) 1989-09-15 1997-01-29 Tanox Biosystems, Inc. Traitement de maladies auto-immunitaires
AU645783B2 (en) 1990-01-23 1994-01-27 Tanox Biosystems, Inc. Extracellular segments of human epsilon immunoglobulin anchoring peptides and antibodies specific therefor
US5281699A (en) 1990-06-01 1994-01-25 Tanox Biosystems, Inc. Treating B cell lymphoma or leukemia by targeting specific epitopes on B cell bound immunoglobulins
US5298420A (en) 1990-08-03 1994-03-29 Tanox Biosystems, Inc. Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface
WO1992007574A1 (fr) 1990-10-25 1992-05-14 Tanox Biosystems, Inc. Glycoproteines associees a des immunoglobulines a liaison membranaire et utilisees comme cibles anticorpales sur des cellules b
US6685939B2 (en) 1991-08-14 2004-02-03 Genentech, Inc. Method of preventing the onset of allergic disorders
SE9102808L (sv) 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
US5958708A (en) 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
CN1167491A (zh) 1994-10-25 1997-12-10 美国联合生物医学公司 用于治疗变态反应的合成IgE膜锚肽免疫原
AU3515597A (en) 1997-05-30 1998-12-30 Tanox Biosystems, Inc. Inhibition of antigen-specific ige production by antigen coupled to membrane igepetide
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
EP2361635A3 (fr) 2000-08-30 2011-09-14 Pfizer Products Inc. Anti-IgE vaccins
CA2624081C (fr) 2005-09-29 2014-09-16 Medimmune, Inc. Methode d'identification d'anticorps specifiques de membranes et leurs utilisations pour cibler les precurseurs producteurs d'immunoglobuline
EP2021027A4 (fr) 2006-05-03 2010-01-27 Guthrie Foundation For Educati Déterminants de surface cellulaire associés à l'immunoglobuline dans le traitement de troubles des lymphocytes b
WO2008116149A2 (fr) 2007-03-22 2008-09-25 Genentech, Inc. Anticorps anti-ige apoptopiques
HUE036920T2 (hu) 2009-02-25 2018-08-28 Academia Sinica Anti-C[epszilon]mX-ellenanyagok, amelyek képesek B-limfocitákon humán mlgE-hez kötõdni
WO2011108008A2 (fr) 2010-03-04 2011-09-09 Transgene Biotek Ltd. Anticorps tbl-cln1 pour une élimination de cellules cancéreuses par induction ciblée d'apoptose, de cdc (cytotoxicité dépendante du complément) et d'adcc (cytotoxicité cellulaire dépendante des anticorps)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105542004A (zh) * 2016-01-12 2016-05-04 中国人民解放军军事医学科学院生物工程研究所 一种抗破伤风毒素的中和性单克隆抗体及其应用
CN105542004B (zh) * 2016-01-12 2019-02-19 中国人民解放军军事医学科学院生物工程研究所 一种抗破伤风毒素的中和性单克隆抗体及其应用
TWI821209B (zh) * 2017-10-31 2023-11-11 合一生技股份有限公司 治療IgE介導的過敏性疾病

Also Published As

Publication number Publication date
US9587034B2 (en) 2017-03-07
EP2838919A1 (fr) 2015-02-25
US20150086558A1 (en) 2015-03-26
WO2013158274A1 (fr) 2013-10-24
EP2838919A4 (fr) 2016-03-23

Similar Documents

Publication Publication Date Title
JP7036860B2 (ja) 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
JP6435381B2 (ja) マトリクスメタロプロティナーゼ９に対する抗体
JP2021138707A (ja) マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法
JP2021006582A (ja) 血漿カリクレイン結合タンパク質
RU2662671C2 (ru) АНТИТЕЛО К АДРЕНОМЕДУЛЛИНУ (ADM) ИЛИ ФРАГМЕНТ АНТИ-ADM АНТИТЕЛА, ИЛИ АНТИ-ADM HE-Ig КАРКАС ДЛЯ ПРИМЕНЕНИЯ В ТЕРАПИИ
JP6067756B2 (ja) マトリックスメタロプロテイナーゼ９に対する抗体
BR112019026907A2 (pt) Anticorpos apenas de cadeia pesadaanti-bcma, polinucleotídeo, vetor, célula,composição farmacêutica, seus usos e método paraproduzir os mesmos
BR112019026803A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
CN103153331B (zh) 靶向于钙粘着蛋白‑11的ec1结构域的人源化抗体及相关组合物和方法
CN109963591A (zh) B7h3抗体-药物偶联物及其医药用途
US20110223169A1 (en) Il-17 antibody inhibitor for treating dry eye
ES2729710T3 (es) Anticuerpo antiadrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje no Ig anti-ADM para la prevención o la reducción de una disfunción orgánica o una insuficiencia orgánica en un paciente que presenta una enfermedad crónica o aguda o una afección aguda
NO338143B1 (no) Stabil, flytende formulering av anti-IgE-antistoff med lav turbiditet, fremstilt artikkel derav, og anvendelse derav til fremstilling av et medikament.
CN104603150A (zh) 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体
JP2015502930A (ja) 慢性若しくは急性疾患又は急性病態に罹患している患者の死亡リスクを低減するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
BR112020012554A2 (pt) anticorpos de cadeia pesada que se ligam a cd22
JP7203904B2 (ja) 抗ｃｃｒ４抗体を用いてサイトカイン発現を媒介する方法
US20240336685A1 (en) Methods for reducing aggregation of bispecific antibodies
CN101679485B (zh) 骨桥蛋白的功能表位、针对该单位的单克隆抗体及它们的应用
JP6159011B2 (ja) Ｃｄ９に対するハイブリドーマクローンおよびモノクローナル抗体
JP2022172170A (ja) 治療抗ＩｇＥ抗体並びにその方法及び組成物
KR20210153039A (ko) 커넥신 43 항체 및 이의 용도
CN113842456B (zh) 一种抗人4-1bb的单克隆抗体制剂及其用途
US11578127B2 (en) Anti-Fc epsilon-R1 alpha (FcεR1α) antibodies, bispecific antigen-binding molecules that bind FcεR1α and CD3, and uses thereof
RU2816994C2 (ru) Антитела к bcma, содержащие только тяжелую цепь

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150506